SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204997864> ?p ?o ?g. }

Showing items 1 to 100 of ±181 with 100 items per page.

W3204997864 endingPage "e703" @default.
W3204997864 startingPage "e690" @default.
W3204997864 abstract "BackgroundThe Global Burden of Diseases, Injuries, and Risk Factors Study 2019 called for innovation in addressing age-related disabilities. Our study aimed to identify and validate a urinary peptidomic profile (UPP) differentiating healthy from unhealthy ageing in the general population, to test the UPP predictor in independent patient cohorts, and to search for targetable molecular pathways underlying age-related chronic diseases.MethodsIn this prospective population study, we used data from participants in the Flemish Study on Environment, Genes and Health Outcomes (FLEMENGHO), done in northern Belgium from 1985 to 2019, and invited participants to a follow-up examination in 2005–10. Participants were eligible if their address was within 15 km of the examination centre and if they had not withdrawn consent in any of the previous examination cycles (1985–2004). All participants (2005–10) were also invited to an additional follow-up examination in 2009–13. Participants who took part in both the 2005–10 follow-up examination and in the additional 2009–13 follow-up visit constituted the derivation dataset, which included their 2005–10 data, and the time-shifted internal validation dataset, which included their 2009–13 data. The remaining participants who only had 2005–10 data constituted the synchronous internal validation dataset. Participants were excluded from analyses if they were incapacitated, had not undergone UPP, or had either missing or outlying (three SDs greater than the mean of all consenting participants) values of body-mass index, plasma glucose, or serum creatinine. The UPP was assessed by capillary electrophoresis coupled with mass spectrometry. The multidimensional UPP signature reflecting ageing was generated from the derivation dataset and validated in the time-shifted internal validation dataset and the synchronous validation dataset. It was further validated in patients with diabetes, COVID-19, or chronic kidney disease (CKD). In FLEMENGHO, the mortality endpoints were all-cause, cardiovascular, and non-cardiovascular mortality; other endpoints were fatal or non-fatal cancer and musculoskeletal disorders. Molecular pathway exploration was done using the Reactome and Kyoto Encyclopedia of Genes and Genomes databases.Findings778 individuals (395 [51%] women and 383 [49%] men; aged 16·2–82·1 years; mean age 50·9 years [SD 15·8]) from the FLEMENGHO cohort had a follow-up examination between 2005 and 2010, of whom 559 participants had a further follow-up from Oct 28, 2009, to March 19, 2013, and made up the derivation (2005–10) and time-shifted internal validation (2009–13) datasets. 219 were examined once and constituted the synchronous internal validation dataset (2005–10). With correction for multiple testing and multivariable adjustment, chronological age was associated with 210 sequenced peptides mainly showing downregulation of collagen fragments. The trained model relating chronological age to UPP, derived by elastic net regression, included 54 peptides from 17 proteins. The UPP-age prediction model explained 76·3% (r=0·87) of chronological age in the derivation dataset, 54·4% (r=0·74) in the time-shifted validation dataset, and 65·3% (r=0·81) in the synchronous internal validation dataset. Compared with chronological age, the predicted UPP-age was greater in patients with diabetes (chronological age 50·8 years [SE 0·37] vs UPP-age 56·9 years [0·30]), COVID‑19 (53·2 years [1·80] vs 58·5 years [1·67]), or CKD (54·6 years [0·97] vs 62·3 years [0·85]; all p<0·0001). In the FLEMENGHO cohort, independent of chronological age, UPP-age was significantly associated with various risk markers related to cardiovascular, metabolic, and renal disease, inflammation, and medication use. Over a median of 12·4 years (IQR 10·8–13·2), total mortality, cardiovascular mortality, and osteoporosis in the population was associated with UPP-age independent of chronological age, with hazard ratios per 10 year increase in UPP-age of 1·54 (95% CI 1·22–1·95) for total mortality, 1·72 (1·20–2·47) for cardiovascular mortality, and 1·40 (1·06–1·85) for osteoporosis and fractures. The most relevant molecular pathways informed by the proteins involved deregulation of collagen biology and extracellular matrix maintenance.InterpretationThe UPP signature indicative of ageing reflects fibrosis and extracellular matrix remodelling and was associated with risk factors and adverse health outcomes in the population and with accelerated ageing in patients. Innovation in addressing disability should shift focus from the ontology of diseases to shared disease mechanisms, in particular ageing-related fibrotic degeneration.FundingEuropean Research Council, Ministry of the Flemish Community, OMRON Healthcare. The Global Burden of Diseases, Injuries, and Risk Factors Study 2019 called for innovation in addressing age-related disabilities. Our study aimed to identify and validate a urinary peptidomic profile (UPP) differentiating healthy from unhealthy ageing in the general population, to test the UPP predictor in independent patient cohorts, and to search for targetable molecular pathways underlying age-related chronic diseases. In this prospective population study, we used data from participants in the Flemish Study on Environment, Genes and Health Outcomes (FLEMENGHO), done in northern Belgium from 1985 to 2019, and invited participants to a follow-up examination in 2005–10. Participants were eligible if their address was within 15 km of the examination centre and if they had not withdrawn consent in any of the previous examination cycles (1985–2004). All participants (2005–10) were also invited to an additional follow-up examination in 2009–13. Participants who took part in both the 2005–10 follow-up examination and in the additional 2009–13 follow-up visit constituted the derivation dataset, which included their 2005–10 data, and the time-shifted internal validation dataset, which included their 2009–13 data. The remaining participants who only had 2005–10 data constituted the synchronous internal validation dataset. Participants were excluded from analyses if they were incapacitated, had not undergone UPP, or had either missing or outlying (three SDs greater than the mean of all consenting participants) values of body-mass index, plasma glucose, or serum creatinine. The UPP was assessed by capillary electrophoresis coupled with mass spectrometry. The multidimensional UPP signature reflecting ageing was generated from the derivation dataset and validated in the time-shifted internal validation dataset and the synchronous validation dataset. It was further validated in patients with diabetes, COVID-19, or chronic kidney disease (CKD). In FLEMENGHO, the mortality endpoints were all-cause, cardiovascular, and non-cardiovascular mortality; other endpoints were fatal or non-fatal cancer and musculoskeletal disorders. Molecular pathway exploration was done using the Reactome and Kyoto Encyclopedia of Genes and Genomes databases. 778 individuals (395 [51%] women and 383 [49%] men; aged 16·2–82·1 years; mean age 50·9 years [SD 15·8]) from the FLEMENGHO cohort had a follow-up examination between 2005 and 2010, of whom 559 participants had a further follow-up from Oct 28, 2009, to March 19, 2013, and made up the derivation (2005–10) and time-shifted internal validation (2009–13) datasets. 219 were examined once and constituted the synchronous internal validation dataset (2005–10). With correction for multiple testing and multivariable adjustment, chronological age was associated with 210 sequenced peptides mainly showing downregulation of collagen fragments. The trained model relating chronological age to UPP, derived by elastic net regression, included 54 peptides from 17 proteins. The UPP-age prediction model explained 76·3% (r=0·87) of chronological age in the derivation dataset, 54·4% (r=0·74) in the time-shifted validation dataset, and 65·3% (r=0·81) in the synchronous internal validation dataset. Compared with chronological age, the predicted UPP-age was greater in patients with diabetes (chronological age 50·8 years [SE 0·37] vs UPP-age 56·9 years [0·30]), COVID‑19 (53·2 years [1·80] vs 58·5 years [1·67]), or CKD (54·6 years [0·97] vs 62·3 years [0·85]; all p<0·0001). In the FLEMENGHO cohort, independent of chronological age, UPP-age was significantly associated with various risk markers related to cardiovascular, metabolic, and renal disease, inflammation, and medication use. Over a median of 12·4 years (IQR 10·8–13·2), total mortality, cardiovascular mortality, and osteoporosis in the population was associated with UPP-age independent of chronological age, with hazard ratios per 10 year increase in UPP-age of 1·54 (95% CI 1·22–1·95) for total mortality, 1·72 (1·20–2·47) for cardiovascular mortality, and 1·40 (1·06–1·85) for osteoporosis and fractures. The most relevant molecular pathways informed by the proteins involved deregulation of collagen biology and extracellular matrix maintenance. The UPP signature indicative of ageing reflects fibrosis and extracellular matrix remodelling and was associated with risk factors and adverse health outcomes in the population and with accelerated ageing in patients. Innovation in addressing disability should shift focus from the ontology of diseases to shared disease mechanisms, in particular ageing-related fibrotic degeneration." @default.
W3204997864 created "2021-10-25" @default.
W3204997864 creator A5000018358 @default.
W3204997864 creator A5002982938 @default.
W3204997864 creator A5003253172 @default.
W3204997864 creator A5005547361 @default.
W3204997864 creator A5007992547 @default.
W3204997864 creator A5011830120 @default.
W3204997864 creator A5013121236 @default.
W3204997864 creator A5013163508 @default.
W3204997864 creator A5016588114 @default.
W3204997864 creator A5023727805 @default.
W3204997864 creator A5024391183 @default.
W3204997864 creator A5024617866 @default.
W3204997864 creator A5025250122 @default.
W3204997864 creator A5028178296 @default.
W3204997864 creator A5028361013 @default.
W3204997864 creator A5030750230 @default.
W3204997864 creator A5031248754 @default.
W3204997864 creator A5034796233 @default.
W3204997864 creator A5037762556 @default.
W3204997864 creator A5037902069 @default.
W3204997864 creator A5042474261 @default.
W3204997864 creator A5044495885 @default.
W3204997864 creator A5045309022 @default.
W3204997864 creator A5052560289 @default.
W3204997864 creator A5056705331 @default.
W3204997864 creator A5057962416 @default.
W3204997864 creator A5058676622 @default.
W3204997864 creator A5061687360 @default.
W3204997864 creator A5062281397 @default.
W3204997864 creator A5072307317 @default.
W3204997864 creator A5073149461 @default.
W3204997864 creator A5073950256 @default.
W3204997864 creator A5075944657 @default.
W3204997864 creator A5076074600 @default.
W3204997864 creator A5077396511 @default.
W3204997864 creator A5080031073 @default.
W3204997864 creator A5080535972 @default.
W3204997864 creator A5082421656 @default.
W3204997864 creator A5086215826 @default.
W3204997864 creator A5087648305 @default.
W3204997864 date "2021-11-01" @default.
W3204997864 modified "2023-10-17" @default.
W3204997864 title "Urinary peptidomic profiles to address age-related disabilities: a prospective population study" @default.
W3204997864 cites W1866542120 @default.
W3204997864 cites W1965498876 @default.
W3204997864 cites W1966862542 @default.
W3204997864 cites W1980783900 @default.
W3204997864 cites W1995565391 @default.
W3204997864 cites W2055864845 @default.
W3204997864 cites W2068343048 @default.
W3204997864 cites W2082134211 @default.
W3204997864 cites W2144899536 @default.
W3204997864 cites W2152647232 @default.
W3204997864 cites W2152956191 @default.
W3204997864 cites W2160234571 @default.
W3204997864 cites W2170446609 @default.
W3204997864 cites W2172557341 @default.
W3204997864 cites W2278988761 @default.
W3204997864 cites W2464904909 @default.
W3204997864 cites W2472456895 @default.
W3204997864 cites W2607031541 @default.
W3204997864 cites W2607291703 @default.
W3204997864 cites W2744377419 @default.
W3204997864 cites W2769225534 @default.
W3204997864 cites W2810453160 @default.
W3204997864 cites W2811426568 @default.
W3204997864 cites W2891879634 @default.
W3204997864 cites W2908618667 @default.
W3204997864 cites W2942090422 @default.
W3204997864 cites W2944301703 @default.
W3204997864 cites W2956714488 @default.
W3204997864 cites W2972965845 @default.
W3204997864 cites W3009723587 @default.
W3204997864 cites W3009862485 @default.
W3204997864 cites W3010268726 @default.
W3204997864 cites W3015682940 @default.
W3204997864 cites W3016853930 @default.
W3204997864 cites W3017299963 @default.
W3204997864 cites W3021249782 @default.
W3204997864 cites W3091845377 @default.
W3204997864 cites W3093350281 @default.
W3204997864 cites W3124816838 @default.
W3204997864 cites W3134919770 @default.
W3204997864 cites W3152802773 @default.
W3204997864 cites W3158207274 @default.
W3204997864 cites W3197607429 @default.
W3204997864 doi "https://doi.org/10.1016/s2666-7568(21)00226-9" @default.
W3204997864 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8566278" @default.
W3204997864 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34766101" @default.
W3204997864 hasPublicationYear "2021" @default.
W3204997864 type Work @default.
W3204997864 sameAs 3204997864 @default.
W3204997864 citedByCount "13" @default.
W3204997864 countsByYear W32049978642021 @default.
W3204997864 countsByYear W32049978642022 @default.
W3204997864 countsByYear W32049978642023 @default.